CJC-1295 / Ipamorelin Blend
Fixed-ratio growth-hormone blend · CJC-1295 (no DAC) 5 mg + Ipamorelin 5 mg
The classic growth hormone (GH) stack in one vial, 5 mg each of CJC-1295 (no DAC) and Ipamorelin, a fixed 1 : 1. People run it for leaner body composition, recovery and deeper sleep. Together they fire a bigger GH pulse than either alone.
At a glance
- Dose
- 400 mcg of blend per shot, 200 mcg to start
- How often
- Once daily; some run it 2–3 times a day
- How
- A small injection under the skin, both in one syringe
- When
- Bedtime on an empty stomach, about 2 hours clear of food
- Cycle
- 8–12 weeks on, then 4–6 weeks off
The 30-second versionEverything on this page, fast
GH support · Lean body composition · Recovery · Two peptides, one shot
The classic growth-hormone stack in one vial. CJC-1295 (no DAC) works the receptor for growth-hormone-releasing hormone (GHRH) and Ipamorelin works the ghrelin receptor, two switches on the same pituitary cell, fired together for a bigger GH pulse. 5 mg of each, one bedtime shot.
The basics
- A pre-mixed powder: 5 mg CJC-1295 (no DAC / Mod-GRF 1-29) + 5 mg Ipamorelin, a 1 : 1 ratio, 10 mg per vial. One vial, one draw, both peptides every time.
- The canonical GHRH + GHRP pairing (a GHRH analog plus a growth-hormone-releasing peptide), the one blend whose two peptides were designed to be injected together. CJC-1295 carries the GHRH signal and Ipamorelin the ghrelin-receptor signal.
Why people use it
- A bigger pulse than either half alone. Two receptors on the same cell, fired at once, is exactly how the body triggers its own GH bursts.
- Raises your own GH instead of injecting it. The pituitary keeps its natural rhythm and feedback in the loop.
- The clean GHRP half. Ipamorelin skips the cortisol and prolactin spike that make GHRP-2 and GHRP-6 harder to run.
- Leaner composition, better recovery, deeper sleep. The growth-hormone goals people run this pair for, in a single nightly draw.
Stacks well with
- BPC-157 + TB-500, or the pre-mixed Wolverine Blend or GLOW Blend. Local tissue repair under the systemic GH backdrop is a different lever, so it adds instead of doubling up.
- Nothing else off the GH shelf. A second GHRH analog (Tesamorelin, Sermorelin) or a second GHRP (GHRP-2, GHRP-6) is the same lever twice; this vial already carries one of each.
Good to know
- Empty stomach is the rule that matters. A meal raises insulin and somatostatin, GH's off-switch, and blunts the pulse. Keep about 2 hours clear either side, and dose at bedtime to ride the body's biggest natural GH burst in deep sleep.
- Check the label says no DAC. A 1 : 1 blend only works with the short-acting no-DAC form. The DAC form is dosed once weekly, which would cram a week of Ipamorelin into a single shot. If your vial says "with DAC," this page's schedule and math don't apply to it.
- GH transiently raises blood sugar and lowers insulin sensitivity, so watch glucose on a longer run.
- Banned in tested sport. Both halves are on the WADA list (S2).
- You can't move one peptide without moving the other. The vial fixes the 1 : 1, so the only lever is the whole dose. Separate vials are the answer when you want a different split.
What it does
The blend people reach for when growth hormone is the goal and one draw beats two vials.
- A bigger GH pulse than either aloneIn 8 healthy men, GHRH(1-29) plus GHRP-2 lifted GH to 140.9 mU/L at 30 minutes, against 32.8 and 109.7 alone.
- Raise your own growth hormoneIn healthy men, an IV dose of Ipamorelin gave one GH pulse, back to very low levels by 6 hours.
- The clean GHRP halfIn conscious pigs, over 200 times Ipamorelin's GH-releasing dose kept ACTH and cortisol at GHRH levels, unlike GHRP-2 and GHRP-6.
- More IGF-1 within a dayIn intensive-care adults, adding GHRH to a GHRP-2 drip doubled GH and lifted IGF-1 (insulin-like growth factor 1) another 40%.
- A big GH release even in obesityIn obese people, GHRH plus GHRP-6 pushed GH to a mean peak of 42.2 µg/L, against 6.8 and 15.7 alone.
Sources:PMID 7586605PMID 10496658FDA 2024PMID 9849822PMID 9024260PMID 8473389
How it works
Two switches on one cell. CJC-1295 works the growth-hormone-releasing hormone (GHRH) receptor on pituitary GH-making cells. Ipamorelin works GHS-R1a, the ghrelin receptor, on the same cell. Together they fire a pulse larger than either alone.
The clean GHRP. Ipamorelin is a growth-hormone-releasing peptide (GHRP). In animal studies it released GH without raising ACTH (adrenocorticotropic hormone) or cortisol, unlike GHRP-2 and GHRP-6. In humans one intravenous dose gave one GH pulse peaking near 40 minutes.
Why no DAC. The blend's short-acting form clears in about 30 minutes and runs 100 mcg one to three times daily. The DAC (Drug Affinity Complex) form, half-life 5.8–8.1 days, runs ~1–2 mg once weekly, which here means a week of Ipamorelin in one shot.
Sources:PubChem CID 91976842PubChem CID 91971820PubChem CID 9831659PMID 16352683PMID 17018654PMID 15817669PMID 9849822PMID 10496658PMID 25331030
How to dose it
One injection under the skin at bedtime, on an empty stomach. Every draw is half CJC-1295 (no DAC), half Ipamorelin.
Dose tiersMost people run 8 units, 200 mcg of each, mixed 10 mg + 2 mL.
- Low, 4 units (200 mcg):
- 100 mcg CJC-1295 (no DAC) + 100 mcg Ipamorelin once daily at bedtime, each on its own page's figure. Start here for the first week, then work up.
- Standard, 8 units (400 mcg):
- 200 mcg of each once daily at bedtime. Ipamorelin sits in its 200–300 mcg band, CJC-1295 at twice its 100 mcg figure; people run both at 100–300 mcg.
- High, 8–12 units (400–600 mcg), 2–3× daily:
- 200–300 mcg of each, 2–3 times daily, fasted, 4–6 hours apart (bedtime, morning, pre-workout). More injections, not a bigger shot; a 10 mg vial then lasts one to two weeks.
How to injectOne injection into body fat. Rotate sites and keep the fasted window.
- Injection site:
- Belly (2–3 cm clear of the navel), love handles or outer thigh. Rotate sites to avoid irritation and lipohypertrophy, fatty lumps from repeat injections.
- Measuring the dose:
- U-100 syringe, 10 mg + 2 mL mix. 4 units hold 200 mcg, 8 units 400 mcg and 12 units 600 mcg, half from each peptide. See the calculator.
- Time of day:
- Bedtime. Twice daily adds a fasted morning shot; three times daily adds a pre-workout shot. Bedtime stays the anchor.
- Food window:
- At least 90–120 minutes after your last meal, and no carb- or fat-heavy food for about 2 hours after. Bedtime cofactors as capsules, not a snack.
Cycle and breaks8–12 week blocks, 4–6 weeks off, so the pituitary stays responsive.
- Standard cycle:
- 8–12 weeks of daily bedtime dosing, roughly two to three and a half vials at 8 units a day.
- Washout:
- 4–6 weeks off between cycles, while GH and IGF-1 drift back toward baseline. Check IGF-1 at the end of the cycle, before the break.
- Lab check:
- IGF-1 is the marker. Baseline first, recheck at 6–8 weeks. Above the age-adjusted reference range, reduce the dose or pause, which means lowering the whole draw.
- Vial life:
- 25 doses at 8 units, 50 at 4 units; 12 units three times daily, under a week. Refrigerate once mixed, finish within four weeks; at 8 units it empties first.
Mixing the vial10 mg + 2 mL bacteriostatic water. The calculator splits any draw.
- Standard mix, 2 mL:
- 10 mg + 2 mL = 5,000 mcg per mL, so each unit holds 50 mcg (25 mcg of each) and 8 units hold 400 mcg (200 mcg each).
- Finer mix, 3 mL:
- 10 mg + 3 mL = 3,333 mcg/mL. 100 mcg each = 6 units, 200 mcg = 12, 300 mcg = 18. Don't switch water mid-vial without redoing the math.
- Read the split:
- The syringe measures total blend. Compare the calculator's per-component readout with CJC-1295 and Ipamorelin. It assumes 5 mg + 5 mg, so check your label.
- Label check:
- Look for no DAC or Mod-GRF 1-29. The DAC form runs about 1–2 mg once weekly, which here would mean 1–2 mg of Ipamorelin in one shot.
Sources:PMID 16352683PMID 17018654PMID 9849822PMID 10496658PMID 25331030
Best time to take it
Implied best time
Bedtime (empty stomach)
Most people inject the blend at bedtime on an empty stomach. The fasted window matters more than the exact hour.
- The body's largest natural GH pulse fires in early deep sleep. A bedtime dose stacks the peptides' pulse on top of that surge.
- Food raises insulin and somatostatin, GH's off-switch, and both blunt the pulse. Keep the dose roughly 2 hours clear of eating.
- Each shot is one short pulse. On a 2–3× daily schedule, fasted morning and pre-workout are the usual extra doses, but bedtime stays the anchor.
Sources:PMID 16352683PMID 10496658
What to stack it with
This vial already holds the two-signal pair. Useful additions come from a different axis; a second GHRH analog or GHRP is the same lever twice.
The blend + BPC-157 / TB-500Local tissue repair under a systemic GH backdrop, the one addition that adds a new lever.
- Why it works:
- BPC-157 promotes new blood vessels and tendon, ligament and gut-lining repair; TB-500 pulls repair cells into damaged tissue. Neither releases GH, so the three don't overlap.
- The protocol:
- The blend 8 units, plus BPC-157 250–500 mcg daily and TB-500 at a higher weekly dose the first 4–6 weeks, then maintenance. Rotate sites; those two need no fasted window.
- Outcome:
- People run it on soft-tissue injuries, post-surgical recovery and training wear. The repair pair also comes pre-mixed as Wolverine Blend or GLOW Blend.
Skip a second GHRH analog or GHRPThe vial already holds one of each. Adding another pushes the same receptor twice.
- A second GHRH analog:
- Tesamorelin and Sermorelin work the same GHRH receptor as the CJC-1295 half. Adding one opens no new pathway and brings no two-signal boost.
- A second GHRP:
- GHRP-2, GHRP-6 and Hexarelin act at GHS-R1a, the Ipamorelin half's receptor, and bring back the prolactin rise and cortisol response Ipamorelin avoids.
- The rule:
- The blend is complete on its own axis. Look to a different axis for the next addition.
The blend + a separate Ipamorelin vialWhen you want more Ipamorelin than the vial gives, top up instead of drawing bigger.
- Why it works:
- At the top of Ipamorelin's 200–300 mcg band the CJC-1295 half hits 300 mcg, three times the 100 mcg figure on CJC-1295's page. A separate vial moves one number alone.
- The protocol:
- The blend 4 units (100 mcg of each) at bedtime, plus Ipamorelin 100–200 mcg co-drawn in the same syringe, for 200–300 mcg of Ipamorelin against 100 mcg of CJC-1295.
- Outcome:
- Reached for by people who ran the components separately and want that split, or whose response plateaus once the CJC-1295 half runs ahead of its figure.
Support nutrients
The three levers are a bigger pulse, steady blood sugar and material to build with.
Lift the somatostatin brakeSomatostatin blocks GH. These lower it for a bigger pulse.
- L-arginine:
- 3–6 g, 30–60 minutes before the bedtime shot, empty stomach. Suppresses somatostatin; skip high-fat meals nearby.
- Glycine:
- 3–10 g at bedtime. Lowers somatostatin and deepens slow-wave sleep, protecting the GH pulse.
- Alpha-GPC:
- 300–600 mg, 30–60 minutes before injecting. Raises acetylcholine, lifting GH and lowering somatostatin.
Counter the glucose riseGH nudges blood sugar up. These keep it level.
- Berberine:
- 500 mg with meals, 2–3× daily, away from the injection. Activates AMPK, the cell's fuel-sensing switch, and supports insulin sensitivity.
- Alpha-lipoic acid (ALA):
- 300–600 mg with a meal. Moves glucose into muscle via GLUT4 and supports mitochondria.
- Magnesium glycinate:
- 300–400 mg elemental magnesium before bed. Supports insulin signaling and the deep sleep where the biggest GH pulse fires.
Supply the building blocksGH and IGF-1 order new tissue. Give them raw material.
- Dietary protein:
- 1.6–2.0 g per kg of body weight per day (≈ 0.7–0.9 g per lb) across 3–4 meals, leucine-rich, last meal clear of the injection.
- ZMA (zinc + magnesium + vitamin B6):
- Zinc 25–30 mg + magnesium 400–500 mg + vitamin B6 10 mg, 30–60 minutes before bed, empty stomach, not with calcium. Low zinc tracks with lower IGF-1.
- Vitamin D3 + K2:
- Vitamin D 2,000–5,000 IU daily (target 40–60 ng/mL) plus vitamin K2 100–200 mcg. D tracks with IGF-1; K2 sends calcium to bone.
Dose calculator
Reconstitution calculator
Calculated for a 1 mL U-100 insulin syringe (100 units/mL).
Units per dose
8 units
Draw this many units on a U-100 syringe
Each unit holds 50 mcg
This dose contains
- CJC-1295 (no DAC)200 mcg
- Ipamorelin200 mcg
Fixed ratio. Every draw carries all of the vial's peptides in the same proportions; only the total changes.
- Volume per dose
- 0.08 mL
- Doses per vial
- 25
- Concentration
- 5 mg/mL
One vial lasts
- Daily
- 25 days
- Every other day
- 50 days
- 5×/week
- 35 days
Research use only. Not for human consumption. Outputs are reference values based on research literature. Verify all measurements independently.
Side effects and what to watch
What people notice. Injection-site soreness and heavier sleep after a bedtime dose. Ipamorelin's 114-patient Phase II trial, 0.03 mg/kg intravenously twice daily for up to seven days, was well tolerated; animal work found no meaningful ACTH, cortisol or prolactin rise. DAC-form CJC-1295 trials reported it relatively well tolerated at 30–60 µg/kg.
A 2006 Phase 2 trial of DAC-form CJC-1295 in HIV-associated lipodystrophy was halted after a participant died; no causal link was established and development stopped.
How people handle it. GH transiently raises blood glucose and lowers insulin sensitivity, so watch glucose on a long block; if IGF-1 tops the age-adjusted range, reduce or pause. That means lowering the whole draw or going to separate vials.
Sources:PMID 25331030PMID 9849822PMID 16352683aidsmap 2006PMID 10496658
Common questions
What is in the vial?
10 mg of powder, 5 mg of CJC-1295 (no DAC, or Mod-GRF 1-29) and 5 mg of Ipamorelin, freeze-dried together at 1 : 1. Other vial sizes exist, so check the label's ratio.
Why the no-DAC form?
The DAC form has a half-life of 5.8–8.1 days and runs about 1–2 mg once weekly; no-DAC clears in about 30 minutes and runs 100 mcg one to three times daily. Only the second fits a daily vial.
How is it dosed?
Most people run 8 units, 400 mcg of blend or 200 mcg of each, once a day at bedtime, fasted, starting at 4 units. Some run it 2–3× daily, each shot fasted.
How much of each peptide is in 8 units?
At the standard mix, 10 mg + 2 mL bacteriostatic water, 8 units hold 200 mcg of CJC-1295 plus 200 mcg of Ipamorelin. Each unit holds 25 mcg of each.
Why blend these two?
Different receptors on the same pituitary cell. CJC-1295 works the GHRH receptor and Ipamorelin the ghrelin receptor, so together they fire a bigger GH pulse than either alone.
Do I need to cycle it?
Most run 8–12 weeks daily, then 4–6 weeks off. Check IGF-1 at the end of the block; above the age-adjusted range, lower the whole draw or pause.
Deep dive
Doses used in studies · Molecular identity · References
10From the researchDoses used in studies
The doses used in the studies behind each component, mostly per kilogram of body weight. CJC-1295's human rows are the DAC form; Ipamorelin's are intravenous.
| Dose | Route | Model | Outcome | Sources: |
|---|---|---|---|---|
| Any | Subcutaneous | No study of the two-peptide blend | No published study has tested CJC-1295 + Ipamorelin as one co-formulated vial; the 5 mg + 5 mg recipe is a market convention, not a studied formulation | |
| None located | Subcutaneous | No primary trial of CJC-1295 no-DAC (Mod-GRF 1-29) | No primary human pharmacokinetic, dosing, or safety trial was located for the short-acting no-DAC form, the form this blend contains; its ~30 min clearance is secondary-sourced | |
| 30–60 µg/kg | Subcutaneous | Human (CJC-1295 WITH DAC; healthy, 21–61 y) | GH up 2–10× for ≥6 d; IGF-1 up 1.5–3× for 9–11 d; best-tolerated 30–60 µg/kg; the DAC molecule, not the form in this vial | PMID 16352683 |
| 60–90 µg/kg | Subcutaneous | Human (CJC-1295 WITH DAC; healthy men) | Preserved GH pulsatility; trough GH +7.5×, mean GH +46%, IGF-1 +45%; the DAC molecule, not the form in this vial | PMID 17018654 |
| Single injection | Injection | Rat (CJC-1295 WITH DAC; Sprague-Dawley) | Plasma detectable >72 h; ~4× GH AUC over 2 h vs hGRF(1-29) | PMID 15817669 |
| EC50 1.3 nmol/L | In vitro | Rat pituitary cells (Ipamorelin) | GH release (Emax ~85%) | PMID 9849822 |
| ED50 ~2.3 nmol/kg | Intravenous | Swine, conscious (Ipamorelin) | GH release; no FSH, LH, prolactin or TSH change; ACTH/cortisol not significantly different from GHRH stimulation | PMID 9849822 |
| 4.21–140.45 nmol/kg | IV infusion (15 min) | Human (Ipamorelin; healthy, n=8/dose) | Dose-proportional GH release; t½ ~2 h | PMID 10496658 |
| 0.03 mg/kg twice daily | Intravenous | Human (Ipamorelin; Phase II, n=114) | Well tolerated; failed efficacy endpoint | PMID 25331030 |
11ChemistryMolecular identity
- Composition
- CJC-1295 (no DAC / Mod-GRF 1-29) 5 mg · Ipamorelin 5 mg = 10 mg per vialCross-source vendor agreement
- Ratio
- 1 : 1 by mass, 50 % CJC-1295 (no DAC) · 50 % IpamorelinCalculated
- Structure / class
- Fixed-ratio, co-lyophilized blend of a GHRH analog and a GHRP in one vial, not a new molecule; each component keeps its own identity and pharmacologyCross-source vendor agreement
- Components
- CJC-1295 no-DAC = Mod-GRF(1-29): C152H252N44O42 · 3,367.9 g/mol (monoiso 3,365.89 Da); Ipamorelin: C38H49N9O5 · 711.9 g/mol (monoiso 711.39 Da) · Aib-His-D-2-Nal-D-Phe-Lys-NH₂ · CAS 170851-70-4 · UNII Y9M3S784Z6PubChem CID 91976842 · PubChem CID 9831659
- No-DAC form
- This blend is the no-DAC form. The DAC molecule is different, CJC-1295 with DAC (DAC:GRF; C165H269N47O46 · 3,647.2 g/mol · CAS 446262-90-4 · UNII 62RC32V9N7), and is dosed once weekly, so a 1 : 1 daily Ipamorelin vial labeled "with DAC" is a schedule mismatch this page's math does not coverPubChem CID 91971820
- Molecular target
- Two receptors on the same pituitary somatotroph: the GHRH receptor (GHRHR) and GHS-R1a, the ghrelin receptorPMID 16352683 · PMID 9849822
- Half-life
- No single clock; ~30 min for CJC-1295 no-DAC (secondary-sourced) and ~2 h for Ipamorelin (human IV, terminal); the ~5.8–8.1 days often quoted for "CJC-1295" belongs to the DAC molecule, which is not in this vialPMID 10496658 · PMID 16352683Half-life curve →
- Regulatory status
- Neither component is an approved drug; no trial has tested the co-formulated blend; both are prohibited in sport (WADA S2, at all times)FDA / WADA Prohibited List
12Primary sourcesReferences
- PubChem CID 91976842PubChem CID 91976842 (CJC-1295 without DAC / Mod-GRF 1-29)
- PubChem CID 91971820PubChem CID 91971820 (CJC-1295 with DAC)
- PubChem CID 9831659PubChem CID 9831659 (Ipamorelin)
- PMID 16352683J Clin Endocrinol Metab 2006 (CJC-1295 human PK/PD/safety, multi-day GH/IGF-1)
- PMID 17018654J Clin Endocrinol Metab 2006 (preserved GH pulsatility under continuous stimulation)
- PMID 15817669Endocrinology 2005 (hGRF(1-29)-albumin bioconjugate; original CJC-1295 ID, rat)
- PMID 9849822Raun et al., Eur. J. Endocrinol. 1998
- PMID 10496658Gobburu et al., Pharm. Res. 1999 (human PK)
- PMID 25331030Beck et al., Int. J. Colorectal Dis. 2014 (Phase II)
- NCT00672074ClinicalTrials.gov NCT00672074 (Phase II ileus)
- aidsmap 2006aidsmap (Jul 2006). Phase 2 lipodystrophy trial halted after participant death
- FDAFDA, bulk drug substances under section 503A (Category 2 history)
- FDA 2024FDA PCAC briefing, Ipamorelin (2024)
- WADAWADA Prohibited List (S2; GHRH analogues and growth-hormone secretagogues prohibited at all times)
- PMID 7586605Tiulpakov et al., Clin. Endocrinol. 1995 (GHRH(1-29) and GHRP-2, alone and together, 8 men)
- PMID 9024260Van den Berghe et al., J. Clin. Endocrinol. Metab. 1997 (GHRH and GHRP-2 infusion in critical illness)
- PMID 8473389Cordido et al., J. Clin. Endocrinol. Metab. 1993 (GHRH plus GHRP-6 in obesity)
Reviewed by Ki Researcher Team · Research use only · Not medical advice · Updated 2026-10-19